MS4A6A Inhibitors
MS4A6A Inhibitors encompass a variety of compounds that indirectly impinge on the functional activity of MS4A6A. The inhibition of Bcl-2 family proteins by compounds such as maritoclax, navitoclax, venetoclax, and obatoclax leads to an increase in apoptotic signaling, which can indirectly reduce the activity or expression levels of MS4A6A. MS4A6A, putatively associated with cell survival and immune cell signaling, could be destabilized in a cellular environment where pro-survival signals are compromised. The antagonism of these proteins creates a cellular state that may not be conducive to the stabilization or activity of MS4A6A, thereby decreasing its functional activity.
In addition, kinase inhibitors like sorafenib, sunitinib, dasatinib, and trametinib target various components of cell survival and proliferation pathways, such as the MAPK andPI3K/Akt pathways. These inhibitors can lead to a cascade of effects culminating in reduced pro-survival signaling, which may be essential for the optimal functionality of MS4A6A. The MEK inhibitors U0126 and trametinib specifically reduce MAPK pathway activity, potentially affecting downstream effectors and indirectly leading to the inhibition of MS4A6A. Compounds like LY294002 and wortmannin act on the PI3K/Akt pathway, a critical pathway for survival and proliferation, the inhibition of which can create an environment less favorable for MS4A6A activity. Rapamycin targets mTOR signaling, another key regulator of cell growth and survival. The inhibition of mTOR by rapamycin can result in reduced cellular support for MS4A6A's functional stability and expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 selectively inhibits the Bcl-2 protein, which is involved in cell survival. The reduction in cell survival signaling could indirectly inhibit MS4A6A by creating a cellular context that is not conducive for its activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets RAF kinases within the MAPK pathway, which can result in the downregulation of survival pathways. Such downregulation can indirectly inhibit MS4A6A by reducing the pro-survival signaling that may be necessary for its function. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including PDGFR and VEGFR, which can decrease angiogenesis and survival signaling. Reduced survival signaling might indirectly inhibit MS4A6A by creating a cellular environment that is less supportive of its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor that can attenuate survival and proliferation signals. This attenuation can indirectly inhibit MS4A6A by reducing the supportive signals required for MS4A6A’s functional activity in the cell. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an MEK inhibitor that decreases ERK phosphorylation, leading to reduced MAPK pathway activity. This reduction can indirectly inhibit MS4A6A by limiting the downstream survival and proliferation signals that are potentially necessary for MS4A6A’s function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits the PI3K/Akt pathway, which can lead to a decrease in cell survival signals. A decrease in these signals can result in an indirect inhibition of MS4A6A, as it may depend on PI3K/Akt pathway activity for its function. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is an inhibitor of MEK, which operates within the MAPK pathway. Inhibition of this pathway can reduce cell proliferation and survival signaling, potentially leading to indirect inhibition of MS4A6A function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that disrupts the PI3K/Akt signaling pathway, leading to reduced survival and growth signals. This disruption can indirectly inhibit MS4A6A by destabilizing the cellular environment that supports its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is crucial for cell growth and survival. Inhibition of mTOR signaling can lead to a less favorable environment for MS4A6A activity, potentially reducing its functional stability and expression. | ||||||